Clinical Trials Browser

Active not recruiting × Solid Tumor × tilsotolimod × Clear all

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor